Alcon bought Aerie Pharmaceuticals Aerie Pharmaceuticals from 11/22/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Alcon completed its acquisition of Aerie Pharmaceuticals for $770 million, or 15.25 per share.

Aerie Pharmaceuticals

Review

Source:

{source} pictogram

investor.alcon.com

Vladimir Petenev

News editor

Write your comment first

News feed

State-owned shareholding of TGC-2 is transferred to GEKH management

7/22/24 TGKB

T-Bank reported for for 6 months of 2024 by RAS

7/22/24 T

Sovcombank reported for 6 months of 2024 by RAS

7/22/24 SVCB

Positive Technologies reported for 6 months of 2024 by RAS

7/22/24 POSI

Positive Technologies reported for 6 months of 2024 by IFRS

7/22/24 POSI

Positive Technologies shipments in the 1st half of the year grew by 8%

7/22/24 POSI

RussNeft reported for 6 months of 2024 by RAS

7/22/24 RNFT

VTB reports for 6 months of 2024 by RAS

7/22/24 VTBR

Samolet+ will answer investors' questions

7/22/24 OTCI

Moscow Exchange wants to conduct 5 pre-IPO transactions in 2024

7/22/24 MOEX